NCT00344422View on ClinicalTrials.gov

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

October 31, 2000

Study Completion Date

June 30, 2004

Conditions
Multiple MyelomaMyelomaM-ProteinMyeloma Proteins
Interventions
DRUG

Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)

All Listed Sponsors
collaborator

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00344422 - Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter